A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial

OBJECTIVES: SARS-CoV2 infection leads to a concomitant pulmonary inflammation. This inflammation is supposed to be the main driver in the pathogenesis of lung failure (Acute Respiratory Distress Syndrome) in COVID-19. Objective of this study is to evaluate the efficacy and safety of a single dose tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Rilinger, Jonathan, Kern, Winfried V., Duerschmied, Daniel, Supady, Alexander, Bode, Christoph, Staudacher, Dawid L., Wengenmayer, Tobias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7267747/
https://www.ncbi.nlm.nih.gov/pubmed/32493514
http://dx.doi.org/10.1186/s13063-020-04447-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7267747/
https://www.ncbi.nlm.nih.gov/pubmed/32493514
http://dx.doi.org/10.1186/s13063-020-04447-3

Ejemplares similares